The classic triad of renal cell carcinoma (flank pain, haematuria, and a palpable abdominal mass) is observed in only 9% of ...

Palvella Therapeutics reports Phase 2 data showing 73% improvement with QTORIN rapamycin gel in cutaneous venous ...

Fast Track designation designed to facilitate the development, and expedite the review, of drugs to treat serious conditions ...

As heart disease remains one of the leading causes of death worldwide, timely and expert cardiovascular care is essential for ...

As of Tuesday, December 16, Relay Therapeutics, Inc.’s RLAY share price has surged by 6.25%, which has investors questioning ...

The latest update is out from Palvella Therapeutics ( (PVLA) ).

Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.

AIIMS Jammu has taken a major stride towards advancing healthcare delivery in the Union Territory with the successful ...

Relay Therapeutics shared interim data for zovegalisib at SABCS 2025, showing consistent efficacy in breast cancer patients.

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L ...

Medtronic reported that its new thrombectomy system, aimed at removing blood clots from the arms and legs, has begun its ...